Advertisement

Tumor Biology

, Volume 35, Issue 5, pp 4041–4045 | Cite as

Association between X-ray repair cross-complementing group 1 Arg194Trp polymorphism and prostate cancer risk

  • Feng He
  • Guizhong Li
  • Libo Man
  • Ning Liu
Research Article

Abstract

X-ray repair cross-complementing group 1 (XRCC1) plays an important role in the maintenance of the genomic integrity. Previous studies on the association between XRCC1 Arg194Trp polymorphism and prostate cancer risk reported conflicting results. To get a more precise assessment of the association between XRCC1 Arg194Trp polymorphism and prostate cancer risk, we performed a meta-analysis of previously published studies. Eligible studies were searched in PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases. Nine studies with a total of 5,407 subjects were finally included into the meta-analysis. Odds ratio (OR) with 95 % confidence interval (95 %CI) was used to assess the association. Overall, there was no obvious association between XRCC1 Arg194Trp polymorphism and prostate cancer risk (Trp vs. Arg: OR = 1.02, 95 %CI 0.84–1.25, P = 0.824; TrpTrp vs. ArgArg: OR = 1.17, 95 %CI 0.83–1.66, P = 0.374; TrpTrp/ArgTrp vs. ArgArg: OR = 1.00, 95 %CI 0.79–1.28, P = 0.990; TrpTrp vs. ArgArg/ArgTrp: OR = 1.20, 95 %CI 0.85–1.68, P = 0.301). Subgroup analysis according to ethnicity also detected no significant association in both Asians and Caucasians. In conclusion, the meta-analysis suggests that there is no obvious association between XRCC1 Arg194Trp polymorphism and prostate cancer risk.

Keywords

XRCC1 Prostate cancer Meta-analysis 

Notes

Conflicts of interest

None

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55:300–18. quiz 23-5.CrossRefPubMedGoogle Scholar
  3. 3.
    Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer. 2009;124:1398–403.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    McCracken M, Olsen M, Chen Jr MS, Jemal A, Thun M, Cokkinides V, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin. 2007;57:190–205.CrossRefPubMedGoogle Scholar
  5. 5.
    Amankwah EK, Sellers TA, Park JY. Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis. 2012;33:1259–69.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Shiloh Y, Ziv Y. The atm protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013;14:197–210.CrossRefGoogle Scholar
  7. 7.
    Schipler A, Iliakis G. DNA double-strand-break complexity levels and their possible contributions to the probability for error-prone processing and repair pathway choice. Nucleic Acids Res. 2013;41:7589–605.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Goodarzi AA, Jeggo PA. The repair and signaling responses to DNA double-strand breaks. Adv Genet. 2013;82:1–45.PubMedGoogle Scholar
  9. 9.
    Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH. Xrcc1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008;18:48–63.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Caldecott KW. Xrcc1 and DNA strand break repair. DNA Repair (Amst). 2003;2:955–69.CrossRefGoogle Scholar
  11. 11.
    Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen. 2004;44:74–82.CrossRefPubMedGoogle Scholar
  12. 12.
    Bartsch H, Dally H, Popanda O, Risch A, Schmezer P. Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res. 2007;174:19–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Xu Z, Hua LX, Qian LX, Yang J, Wang XR, Zhang W, et al. Relationship between xrcc1 polymorphisms and susceptibility to prostate cancer in men from Han, Southern China. Asian J Androl. 2007;9:331–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Hamano T, Matsui H, Ohtake N, Nakata S, Suzuki K. Polymorphisms of DNA repair genes, xrcc1 and xrcc3, and susceptibility to familial prostate cancer in a Japanese population. Asia Pac J Clin Oncol. 2008;4:21–6.CrossRefGoogle Scholar
  15. 15.
    Gao R, Price DK, Dahut WL, Reed E, Figg WD. Genetic polymorphisms in xrcc1 associated with radiation therapy in prostate cancer. Cancer Biol Ther. 2010;10:13–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Agalliu I, Kwon EM, Salinas CA, Koopmeiners JS, Ostrander EA, Stanford JL. Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. Cancer Causes Control. 2010;21:289–300.CrossRefPubMedGoogle Scholar
  17. 17.
    van Gils CH, Bostick RM, Stern MC, Taylor JA. Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the xrcc1 gene. Cancer Epidemiol Biomarkers Prev. 2002;11:1279–84.PubMedGoogle Scholar
  18. 18.
    Mandal RK, Gangwar R, Mandhani A, Mittal RD. DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group d polymorphisms and risk of prostate cancer: a study from north India. DNA Cell Biol. 2010;29:183–90.CrossRefPubMedGoogle Scholar
  19. 19.
    Hirata H, Hinoda Y, Tanaka Y, Okayama N, Suehiro Y, Kawamoto K, et al. Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer. 2007;43:231–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Mittal RD, Mandal RK, Gangwar R. Base excision repair pathway genes polymorphism in prostate and bladder cancer risk in north Indian population. Mech Ageing Dev. 2012;133:127–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  23. 23.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  24. 24.
    Ginsberg G, Angle K, Guyton K, Sonawane B. Polymorphism in the DNA repair enzyme xrcc1: utility of current database and implications for human health risk assessment. Mutat Res. 2011;727:1–15.CrossRefPubMedGoogle Scholar
  25. 25.
    Liu F, Li B, Wei Y, Yan L, Wen T, Zhao J, et al. Xrcc1 genetic polymorphism arg399gln and hepatocellular carcinoma risk: a meta-analysis. Liver Int. 2011;31:802–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Karahalil B, Bohr VA, Wilson 3rd DM. Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk. Hum Exp Toxicol. 2012;31:981–1005.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Urinary SurgeryBeijing Jishuitan HospitalBeijingChina

Personalised recommendations